Contents Volume 73 Issue 1 | ARD January 2014 The Eular Journal 56 Treatment of diffuse systemic sclerosis with Editorial hyperimmune caprine serum (AIMSPRO): a phase II 1 Classifi cation criteria for Sjogren’s syndrome: nothing OPEN ACCESS double-blind placebo-controlled trial ever stands still! N P Quillinan, D McIntosh, J Vernes, S Haq, C P Denton S J Bowman, R I Fox Ann Rheum Dis: first published as on 1 January 2014. Downloaded from 62 Prevalence of comorbidities in rheumatoid arthritis Viewpoint and evaluation of their monitoring: results of an OPEN ACCESS international, cross-sectional study (COMORA) 3 Proposal for a new nomenclature of disease-modifying M Dougados, M Soubrier, A Antunez, P Balint, A Balsa, antirheumatic drugs M H Buch, G Casado, J Detert, B El-zorkany, P Emery, J S Smolen, D van der Heijde, K P Machold, D Aletaha, N Hajjaj-Hassouni, M Harigai, S-F Luo, R Kurucz, G Maciel, R Landewé E M Mola, C M Montecucco, I McInnes, H Radner, J S Smolen, Y-W Song, H E Vonkeman, K Winthrop, J Kay Recommendations 69 A randomised, double-blind, parallel-group study of the 6 Treating spondyloarthritis, including ankylosing safety and effi cacy of subcutaneous tocilizumab versus Editor spondylitis and psoriatic arthritis, to target: OPEN ACCESS intravenous tocilizumab in combination with traditional Tore K Kvien OPEN ACCESS recommendations of an international task force disease-modifying antirheumatic drugs in patients with Associate Editors J S Smolen, J Braun, M Dougados, P Emery, O FitzGerald, moderate to severe rheumatoid arthritis (SUMMACTA Francis Berenbaum P Helliwell, A Kavanaugh, T K Kvien, R Landewé, T Luger, study) Hans Bijlsma P Mease, I Olivieri, J Reveille, C Ritchlin, M Rudwaleit, G R Burmester, A Rubbert-Roth, A Cantagrel, S Hall, David Pisetsky M Schoels, J Sieper, M de Wit, X Baraliakos, N Betteridge, P Leszczynski, D Feldman, M J Rangaraj, G Roane, Dimitrios Boumpas R Burgos-Vargas, E Collantes-Estevez, A Deodhar, D Elewaut, C Ludivico, P Lu, L Rowell, M Bao, E F Mysler Gerd Burmester L Gossec, M Jongkees, M Maccarone, K Redlich, Mary Crow F van den Bosch, J Cheng-Chung Wei, K Winthrop, Iain McInnes D van der Heijde 75 Remission induction comparing infl iximab and Editorial offi ce high-dose intravenous steroid, followed by treat-to- Annals of the Rheumatic Diseases 17 International recommendations for the assessment of target: a double-blind, randomised, controlled trial in BMJ Publishing Group Ltd autoantibodies to cellular antigens referred to as BMA House new-onset, treatment-naive, rheumatoid arthritis (the Tavistock Square anti-nuclear antibodies IDEA study) London WCIH 9JR,UK N Agmon-Levin, J Damoiseaux, C Kallenberg, U Sack, J L Nam, E Villeneuve, E M A Hensor, P G Conaghan, T: +44 (0)20 7383 6250 T Witte, M Herold, X Bossuyt, L Musset, R Cervera, H I Keen, M H Buch, A K Gough, M J Green, P S Helliwell, F: +44 (0)20 7383 6668 A Plaza-Lopez, C Dias, M José Sousa, A Radice, C Eriksson, A M Keenan, A W Morgan, M Quinn, R Reece, E: [email protected] O Hultgren, M Viander, M Khamashta, S Regenass, D M van der Heijde, R J Wakefi eld, P Emery ISSN: 0003-4967 (print) L E C Andrade, A Wiik, A Tincani, J Rönnelid, D B Bloch, ISSN: 1468-2060 (online) M J Fritzler, E K L Chan, I Garcia-De La Torre, Impact Factor: 9.111 K N Konstantinov, R Lahita, M Wilson, O Vainio, N Fabien, 86 Head-to-head comparison of subcutaneous abatacept R A Sinico, P Meroni, Y Shoenfeld versus adalimumab for rheumatoid arthritis: two-year http://ard.bmj.com/ Disclaimer: ARD is owned and published by OPEN ACCESS BMJ Publishing Group Ltd (a wholly owned effi cacy and safety fi ndings from AMPLE trial subsidiary of the British Medical Association) M Schiff, M E Weinblatt, R Valente, D van der Heijde, and the European League Against Rheumatism. The G Citera, A Elegbe, M Maldonado, R Fleischmann owners grant editorial freedom tothe Editor of ARD. Review ARD follows guidelines on editorial independence 24 Hepatitis C virus-induced vasculitis: therapeutic options produced by the World Association of Medical Editors P Cacoub, B Terrier, D Saadoun 95 Assessment of short-term symptomatic effi cacy and the code on good publication practice ofthe Committee on Publication Ethics. of tocilizumab in ankylosing spondylitis: results of ARD is intended for medical professionals and is OPEN ACCESS randomised, placebo-controlled trials on September 29, 2021 by guest. Protected copyright. provided without warranty, express or implied. Clinical and epidemiological research J Sieper, B Porter-Brown, L Thompson, O Harari, M Dougados Statements in the journal are the responsibility of their authors and advertisers and not authors’ 31 Comparison of the American-European Consensus institutions the BMJ Publishing Group, the European League Against Rheumatism or the Group Sjögren’s syndrome classifi cation criteria to BMA unless otherwise specifi ed or determined newly proposed American College of Rheumatology by law. Acceptance of advertising does not imply endorsement. criteria in a large, carefully characterised sicca cohort To the fullest extent permitted by law, the BMJ A Rasmussen, J A Ice, H Li, K Grundahl, J A Kelly, L Radfar, Publishing Group shall not be liable for any loss, injury D U Stone, K S Hefner, J-M Anaya, M Rohrer, or damage resulting from the use of ARD or any R Gopalakrishnan, G D Houston, D M Lewis, J Chodosh, information in it whether based on contract, tort, or J B Harley, P Hughes, J S Maier-Moore, C G Montgomery, otherwise. Readers are advised to verify any information they choose to rely on. N L Rhodus, A D Farris, B M Segal, R Jonsson, C J Lessard, R H Scofi eld, K L M Sivils Copyright: © 2014 BMJ Publishing Group and European League Against Rheumatism. All rights MORE CONTENTS ᭤ reserved; no part of this publication may be reproduced 39 Effi cacy of certolizumab pegol on signs and symptoms stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying of axial spondyloarthritis including ankylosing This article has been chosen by the Editor to be of special interest recording, or otherwise without prior permission OPEN ACCESS spondylitis: 24-week results of a double-blind or importance and is freely available online. ARD is published by BMJ Publishing Group Ltd typeset randomised placebo-controlled Phase 3 study by Techset and printed in the UK on acid-free paper. This article has been made freely available online under the BMJ R Landewé, J Braun, A Deodhar, M Dougados, Annals of the Rheumatic Diseases (ISSN No: Journals Open Access scheme. 0003-4967) is published monthly by BMJ Publishing W P Maksymowych, P J Mease, J D Reveille, M Rudwaleit, OPEN ACCESS Group and distributed in the USA by Air Business Ltd. D van der Heijde, C Stach, B Hoepken, A Fichtner, G Coteur, See http://ard.bmj.com/site/about/guidelines.xhtml#open Periodicals postage paid at Jamaica NY 11431 M de Longueville, J Sieper POSTMASTER: send address changes to Annals of the Rheumatic Diseases, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, 48 Effect of certolizumab pegol on signs and symptoms Jamaica, NY 11434, USA. in patients with psoriatic arthritis: 24-week results of This journal is a member of and subscribes to the principles of the OPEN ACCESS a Phase 3 double-blind randomised placebo-controlled Committee on Publication Ethics study (RAPID-PsA) www.publicationethics.org.uk P J Mease, R Fleischmann, A A Deodhar, J Wollenhaupt, M Khraishi, D Kielar, F Woltering, C Stach, B Hoepken, T Arledge, D van der Heijde Receive regular table of contents by email. Register using this QR code. Contents Volume 73 Issue 1 | ARD January 2014 101 Effi cacy and safety of infl iximab plus naproxen versus 177 Tophaceous gout and high level of hyperuricaemia naproxen alone in patients with early, active axial are both associated with increased risk of mortality in OPEN ACCESS spondyloarthritis: results from the double-blind, patients with gout placebo-controlled INFAST study, Part 1 F Perez-Ruiz, L Martínez-Indart, L Carmona, J Sieper, J Lenaerts, J Wollenhaupt, M Rudwaleit, V I Mazurov, A M Herrero-Beites, J I Pijoan, E Krishnan Ann Rheum Dis: first published as on 1 January 2014. Downloaded from L Myasoutova, S Park, Y Song, R Yao, D Chitkara, N Vastesaeger, on Behalf of All INFAST Investigators 183 Effi cacy and safety of epratuzumab in patients with moderate/severe active systemic lupus 108 Maintenance of biologic-free remission with naproxen OPEN ACCESS erythematosus: results from EMBLEM, a phase or no treatment in patients with early, active axial IIb, randomised, double-blind, placebo-controlled, OPEN ACCESS spondyloarthritis: results from a 6-month, randomised, multicentre study open-label follow-up study, INFAST Part 2 D J Wallace, K Kalunian, M A Petri, V Strand, J Sieper, J Lenaerts, J Wollenhaupt, M Rudwaleit, V I Mazurov, F A Houssiau, M Pike, B Kilgallen, S Bongardt, A Barry, L Myasoutova, S Park, Y Song, R Yao, D Chitkara, L Kelley, C Gordon N Vastesaeger, on Behalf of All INFAST Investigators 191 Expert consensus for performing right heart 114 Performance of the 2010 ACR/EULAR classifi cation catheterisation for suspected pulmonary arterial criteria for rheumatoid arthritis: a systematic literature hypertension in systemic sclerosis: a Delphi review consensus study with cluster analysis H Radner, T Neogi, J S Smolen, D Aletaha J Avouac, D Huscher, D E Furst, C F Opitz, O Distler, Y Allanore, for the EPOSS group 124 Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: